No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

BACKGROUND: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Liver Cancer
Hlavní autoři: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Kawano, Reo, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2018
Témata:
Original Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249591/
https://ncbi.nlm.nih.gov/pubmed/30488024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487858
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky